The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

The firm is seeking accelerated approval for UX111 using reductions in levels of heparan sulfate in cerebrospinal fluid as a surrogate endpoint.

Ultragenyx (RARE) announced the FDA has accepted for review the Biologics License Application, or BLA, seeking accelerated approval for UX111 ...

Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The ...

HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report ...

Last week, you might have seen that Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) released its yearly result to ...

The biotechnology company, Ultragenyx, has reported a successful fourth quarter and full year 2024 financial results ...

Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc Howard Horn; ...

RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.

Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $98.0, a ...